In early 2023, the American Society of Anesthesiologists (ASA) published new guidelines to provide best practices and recommendations for monitoring and antagonism of neuromuscular blockade, with a focus on addressing practice deficiencies and recognizing opportunities to improve patient care in preventing post-operative residual neuromuscular blockade (NMB). Misconceptions about the reliability of non-quantitative methods of train-of-four (TOF) monitoring remain, leading to inadequate assessment of post-operative NMB and inaccurate assessment of the need for reversal. The 2023 ASA guidelines make specific recommendations regarding TOF monitoring methods and use of specific agents for NMB reversal, which inform the current standard of care in anesthesia practice.
In the second episode of the CMEOCast podcast series, J.Ross Renew, MD and Dru Riddle, DNP, CRNA will guide learners through strategies to best incorporate recommendations from the 2023 ASA guidelines into clinical practice.
Incorporate best practices in the utilization of quantitative TOF monitoring of neuromuscular blockade.
Supported by an educational grant from Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Physicians, nurse practitioners (NPs), physician associates (PAs), nurses, and pharmacists specializing in anesthesiology or surgery
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
Dr. Renew reports the following financial relationships:
Research Support: Merck & Co., Inc (Funds to Mayo Clinic)
Dr. Riddle reports the following financial relationships:
Speakers Bureau: Acacia Pharma/Eagle Pharmaceuticals, Inc.
Disclosures were obtained from the following peer reviewer and CME Outfitters, LLC, staff, with no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Call us at 877.CME.PROS (877.263.7767).